Drug intelligence / Profile preview

Elgaba

Development stage: Unknown
Lead developer: Elliott Labs
Modality: Small Molecules
Administration: Oral

Overview

**Elgaba** is an oral fixed-dose pharmaceutical product marketed by Elliott Labs that contains **gabapentin** and **methylcobalamin**. Commercial product listings identify the tablet strength as gabapentin 300 mg plus methylcobalamin 500 mcg and describe its use for neuropathic pain. Gabapentin binds with high affinity to the alpha-2/delta auxiliary subunit of voltage-activated calcium channels, reducing neuronal excitability and pain-signal transmission; methylcobalamin is an active vitamin B12 form used to support cobalamin-dependent neuronal metabolism. ([1mg.com](https://www.1mg.com/drugs/elgaba-tablet-982292))

Brand names: Elgaba
Other names: gabapentin + methylcobalamin

Targets

GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)MTR (Methionine synthase)

Beyond the preview

Go deeper on Elgaba.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elgaba.

Explore the full profile